Jack A. Khattar sold $5.9M of SUPN
President, CEO at SUPERNUS PHARMACEUTICALS, INC.. 140,000 shares at an average of $42.02, traded Aug 6, 2025, filed Aug 8, 2025.
Score components
- +25RoleCEO
- +25Trade size$5.9M at market
- +5Share of holdings soldSold 13% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +11.6%, 3m +11.6%, 6m +25.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-039302, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 6, 2025 | MOption exercise Common Stock10b5-1 | +60,000 | $12.98 | $779k | 1,068,683 | Aug 8, 2025 |
| Aug 6, 2025 | SOpen-market sale Common Stock10b5-1 | -38,500 | $40.24 | $1.5M | 1,030,183 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Common Stock10b5-1 | +60,000 | $12.98 | $779k | 1,090,183 | Aug 8, 2025 |
| Aug 6, 2025 | SOpen-market sale Common Stock10b5-1 | -38,000 | $42.00 | $1.6M | 1,052,183 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Common Stock10b5-1 | +81,250 | $25.30 | $2.1M | 1,133,433 | Aug 8, 2025 |
| Aug 6, 2025 | SOpen-market sale Common Stock10b5-1 | -63,500 | $43.12 | $2.7M | 1,069,933 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -60,000 | $0.00 | $0 | 195,000 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -60,000 | $0.00 | $0 | 135,000 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -81,250 | $0.00 | $0 | 243,750 | Aug 8, 2025 |
Related signals
Other insiders at SUPERNUS PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | SUPERNUS PHARMACEUTICALS, INC. | Padmanabh P. Bhatt Sr. VP of IP, CSO | $5.4M 107,250 shares | -160% | |
| 43Moderate | SUPERNUS PHARMACEUTICALS, INC. | Frederick M. Hudson director | $272k 5,369 shares | -8% | |
| 45Moderate | SUPERNUS PHARMACEUTICALS, INC. | Jack A. Khattar President, CEO | $1.8M 35,000 shares | -4% | |
| 53Moderate | SUPERNUS PHARMACEUTICALS, INC. | William Todd Horich SVP, Commercial Operations | $484k 8,877 shares | -100% | |
| 24Weak | SUPERNUS PHARMACEUTICALS, INC. | Frank Mottola SVP, Chief Tech. Ops. Officer | $87k 1,623 shares | -8% | |
| 50Moderate | SUPERNUS PHARMACEUTICALS, INC. | Georges Gemayel director | $1.0M 18,787 shares | -49% | |
| 21Weak | SUPERNUS PHARMACEUTICALS, INC. | Bethany Sensenig director | $228k 4,475 shares | -100% | |
| 33Weak | SUPERNUS PHARMACEUTICALS, INC. | Frank Mottola SVP, Chief Tech. Ops. Officer | $1.0M 20,000 shares | -98% | |
| 13Weak | SUPERNUS PHARMACEUTICALS, INC. | Padmanabh P. Bhatt Sr. VP of IP, CSO | $32k 710 shares | -5% | |
| 23Weak | SUPERNUS PHARMACEUTICALS, INC. | Jack A. Khattar President, CEO | $3.0M 59,900 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.